# A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma

> **NCT05603039** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Advanced Liver Cancer

## Interventions

- **DRUG:** QL1706
- **DRUG:** QL1604
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05603039
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-01
- **Primary completion:** 2023-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05603039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05603039, "A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT05603039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*